Novavax gets NIH grant

Business of Biotech

Novavax, Inc. (NASDAQ:NVAX) has received a Small Business and Innovation Research grant from the National Institute of Allergy and Infectious Diseases. The grant will support a segment of the Company’s preclinical research program for the respiratory syncytial virus (RSV) particle-based vaccine. As previously announced, Novavax has an RSV vaccine candidate in preclinical development, which is directed against a protein on the surface of the virus, the “F” or “fusion” protein. The grant, valued at approximately $246,000, will support continued preclinical development of the RSV-F vaccine candidate using the bovine calf model.

 Read the release.

Business of Biotech  |  Email This Post  |  Printer Friendly
Tags: ,

Leave a Reply

Your email address will not be published. Required fields are marked *

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>